Chiron ends clinical trial of HIV treatment
BY Advocate.com Editors
October 25 2002 12:00 AM ET
Chiron Corp. announced Wednesday that it is ending the development of three compounds, including a recombinant form of interleukin-2 being studied in a Phase III trial for the treatment of patients with HIV. The company had been expected to complete the clinical trial, including patient follow-up, in 2007. Chiron is now reviewing data for a possible regulatory submission for approval of IL-2 only in a small subset of HIV-positive patients who do not receive any response to other anti-HIV medications. The company also stopped development of compounds intended to treat cystic fibrosis and hepatitis B.
- California Becomes First State to Ban Gay, Trans 'Panic' Defenses
- The New 'Republicans Are People Too' Twitter Campaign Is An Epic Fail
- Read This Mich. Democrat's Epic Response to Antigay Group's 'Pile of Excrement'
- GLAAD Issues Record Number of 'Excellent' Ratings for TV Networks
- 5 Times the U.N. Resolved, Then Failed, to End Homophobia Worldwide
- Op-ed: What Barney Frank Still Gets Wrong on ENDA